May 17th 2024
Clearly Me uses portraiture to spotlight the journeys of psoriasis patients Katie Lowes, DaQuane Cherry, Ayesha Patrick, and Joanna “JoJo” Pomerantz.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Phase 3 results show risankizumab outperforms secukinumab
January 17th 2020Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.
Psoriasis cream safe, effective suggests EU phase 3 results
December 23rd 2019Results from an EU phase 3 clinical trial of a combination of betamethasone dipropionate and calcipotriene cream showed improved patient convenience, quality of life and efficacy compared to a betamethasone dipropionate and calcipotriene gel for patients with plaque psoriasis.
IL-17 potential therapeutic target for pustular psoriasis
November 19th 2019Researchers performed a systematic review of available reports on the therapeutic benefit of interleukin (IL)-17/T-helper 17 (Th17) axis inhibitors in patients with generalized pustular psoriasis (GPP). Read what they discovered in this article.
Phototherapy safe, effective for psoriasis
November 8th 2019The 2019 joint American Academy of Dermatology and National Psoriasis Foundation phototherapy treatment of psoriasis guidelines comprehensively updates dermatologists and other providers on the state-of-the art use of various light modalities to treat psoriasis patients.
Anti-TNF therapy may be less effective in women with psoriasis
October 29th 2019A study recently explored the differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders with moderate-to-severe psoriasis. Read what researchers discovered in this article.
Interleukin-29 for inflammatory autoimmune diseases
October 29th 2019Interleukin-29 (IL-29) is a newly discovered cytokine that has become the subject of increased research attention for its role in inflammation and inflammatory autoimmune disorders and therefore as a target for novel therapeutic development.
40 years of dermatology breakthroughs at a glance
October 15th 2019With 4 decades of dermatology advances, we asked the very dermatologist experts who we often contact to help us to report on the milestones to weigh in on what they think have made the most difference in theirs and their patients’ lives.
Is psoriasis a risk factor for cardiometabolic disease in women?
October 8th 2019It is well established that psoriasis is associated with cardiometabolic disease, though the reason why remains unclear. This study followed pregnant women and mothers with psoriasis over an 11 year period to gain insight into the link between the immune-mediated skin disease and cardiometabolic disease.
New insights expand available psoriasis treatments
August 15th 2019New psoriasis treatments are making their way to market. This supplement and the corresponding August issue take a broad look at the evolving understanding of the pathogenesis of psoriasis, the expanding treatment armamentarium, co-morbidity considerations, and financial considerations of new technologies.